8HQN
Activation mechanism of GPR132 by 9(S)-HODE
8HQN の概要
エントリーDOI | 10.2210/pdb8hqn/pdb |
EMDBエントリー | 34951 |
分子名称 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, scFv16, ... (6 entities in total) |
機能のキーワード | gpcr, gpr132, membrane protein |
由来する生物種 | Homo sapiens (human) 詳細 |
タンパク質・核酸の鎖数 | 5 |
化学式量合計 | 170341.93 |
構造登録者 | |
主引用文献 | Wang, J.L.,Dou, X.D.,Cheng, J.,Gao, M.X.,Xu, G.F.,Ding, W.,Ding, J.H.,Li, Y.,Wang, S.H.,Ji, Z.W.,Zhao, X.Y.,Huo, T.Y.,Zhang, C.F.,Liu, Y.M.,Sha, X.Y.,Gao, J.R.,Zhang, W.H.,Hao, Y.,Zhang, C.,Sun, J.P.,Jiao, N.,Yu, X. Functional screening and rational design of compounds targeting GPR132 to treat diabetes. Nat Metab, 5:1726-1746, 2023 Cited by PubMed Abstract: Chronic inflammation due to islet-residing macrophages plays key roles in the development of type 2 diabetes mellitus. By systematically profiling intra-islet lipid-transmembrane receptor signalling in islet-resident macrophages, we identified endogenous 9(S)-hydroxy-10,12-octadecadienoic acid-G-protein-coupled receptor 132 (GPR132)-Gi signalling as a significant contributor to islet macrophage reprogramming and found that GPR132 deficiency in macrophages reversed metabolic disorders in mice fed a high-fat diet. The cryo-electron microscopy structures of GPR132 bound with two endogenous agonists, N-palmitoylglycine and 9(S)-hydroxy-10,12-octadecadienoic acid, enabled us to rationally design both GPR132 agonists and antagonists with high potency and selectivity through stepwise translational approaches. We ultimately identified a selective GPR132 antagonist, NOX-6-18, that modulates macrophage reprogramming within pancreatic islets, decreases weight gain and enhances glucose metabolism in mice fed a high-fat diet. Our study not only illustrates that intra-islet lipid signalling contributes to islet macrophage reprogramming but also provides a broadly applicable strategy for the identification of important G-protein-coupled receptor targets in pathophysiological processes, followed by the rational design of therapeutic leads for refractory diseases such as diabetes. PubMed: 37770763DOI: 10.1038/s42255-023-00899-4 主引用文献が同じPDBエントリー |
実験手法 | ELECTRON MICROSCOPY (3 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
